85 years old Newly diagnosed diabetes HbA1c 7.8% � LabReportNew - 2026-07-13T171906.033.pdf FBS 134 mg/dL PPBS 199 mg/dL eGFR 38 mL/min/1.73 m² (CKD 3b) Multiple comorbidities (HTN, dyslipidemia)b12>2000. C/o burning feet
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
diabetes mellitus elderly management glycemic targets CKD
Finding Sources
Finding Sources
Searching PubMed
diabetes CKD antidiabetic drug selection eGFR
Finding Sources
Finding Sources
Searching the Web
diabetes management elderly 85 years CKD 3b eGFR 38 HbA1c target drug choice 2025 guidelines
Searching the Web
burning feet high B12 2000 diabetes neuropathy cause differential diagnosis
Searching PubMed
elderly diabetes glycemic target HbA1c older adults frailty
I now have comprehensive information to provide a detailed clinical response. Let me compile everything.
Clinical Assessment & Management Plan
Patient: 85F/M | Newly diagnosed T2DM | HbA1c 7.8% | FBS 134 | PPBS 199 | eGFR 38 (CKD 3b) | HTN + Dyslipidemia | B12 >2000 | Burning feet
1. Glycemic Target - Individualize for Age + CKD
At 85 years with multiple comorbidities and CKD 3b, the priority shifts from tight glycemic control to safety and quality of life. Per ADA 2025 and UK Kidney guidelines:
| Patient Category | HbA1c Target |
|---|---|
| Healthy elderly, long life expectancy | <7.5% |
| Complex/intermediate (multiple comorbidities, CKD) | <8.0% |
| Very frail, limited life expectancy | <8.5% or avoid hypoglycemia focus |
For this patient: Target HbA1c 7.5-8.0% - the current 7.8% is actually within an acceptable range for this age group. Avoid overtreating - hypoglycemia risk in an 85-year-old causes falls, fractures, cardiac events, and cognitive harm far exceeding the risk from mild hyperglycemia.
2. Drug Selection with eGFR 38 (CKD 3b)
This is the most critical decision. eGFR 38 severely restricts choices:
✅ PREFERRED / SAFE
| Drug | Dose Adjustment | Notes |
|---|---|---|
| Linagliptin (DPP-4i) | No dose adjustment needed | Only DPP-4i that is renally safe at any eGFR - first-line choice here |
| Metformin | Use with caution; reduce dose | eGFR 30-45: use 50% dose max; monitor every 3 months. ADA 2025: can continue if eGFR ≥30 |
| Glipizide (sulfonylurea) | Use with caution at eGFR <30 | Short-acting, less active metabolites - safer than glimepiride at eGFR 38. But - high hypoglycemia risk in elderly - avoid if possible |
| Insulin (basal) | No specific dose adjustment | If needed; careful titration; start low |
⚠️ DOSE ADJUSTMENT REQUIRED
| Drug | Status at eGFR 38 |
|---|---|
| Sitagliptin | Reduce to 50 mg/day (eGFR 30-49) |
| Other DPP-4i (saxagliptin, alogliptin) | Dose reduce required |
| GLP-1 RA (liraglutide, dulaglutide) | No dose adjustment needed but GI side effects risk dehydration - caution in elderly with CKD |
❌ AVOID / CONTRAINDICATED
| Drug | Reason |
|---|---|
| SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) | Avoid at eGFR <45 (efficacy lost + volume depletion risk). Note: ADA 2025 says SGLT2i can be initiated if eGFR ≥20 for renoprotection in CKD with albuminuria - check UACR first |
| Glimepiride | Avoid at eGFR <60 - active metabolites accumulate, prolonged hypoglycemia |
| Glyburide/Glibenclamide | Absolutely avoid in elderly with CKD |
| Acarbose | Serum creatinine >2 mg/dL: avoid |
Recommended Regimen:
Linagliptin 5 mg OD (first choice - no renal dose adjustment, no hypoglycemia, well tolerated in elderly) ± low-dose metformin (if tolerated, eGFR stable ≥30).
UACR check is mandatory: If UACR >200 mg/g, ADA 2025 recommends SGLT2i (empagliflozin/dapagliflozin) even at eGFR 38, primarily for renoprotection - per the Cochrane 2024 SGLT2i in CKD review and the JAMA 2026 meta-analysis showing benefit across eGFR ranges.
3. Burning Feet - The B12 Plot Twist
B12 >2000 pg/mL is elevated - this effectively rules out B12 deficiency as the cause of burning feet. High B12 can itself indicate an underlying issue (liver disease, myeloproliferative disorder, solid tumor - worth checking LFTs and CBC if not done).
Differential for burning feet in this patient:
| Cause | Likelihood | Notes |
|---|---|---|
| Diabetic peripheral neuropathy | HIGH | Even newly diagnosed - hyperglycemia may have been present for years before diagnosis; 50% of T2DM patients have neuropathy at diagnosis |
| Uremic/CKD neuropathy | MODERATE-HIGH | eGFR 38 with CKD causes toxic peripheral neuropathy - burning paresthesias are classic, as noted in Textbook of Family Medicine 9e |
| Small fiber neuropathy | Consider | Normal NCS doesn't rule out - requires skin biopsy |
| B12 excess (toxic?) | Low but possible | Paradoxically, very high B12 can rarely cause neuropathy; also masks functional deficiency |
| Medication-induced | Check drug list | Statins, some antihypertensives |
Investigations for burning feet:
- Nerve conduction studies / EMG
- TSH (hypothyroidism)
- Serum B12 active fraction (holotranscobalamin) if functional deficiency suspected
- Check for B12 cause: LFTs, CBC, LDH, uric acid
- Skin biopsy if small fiber neuropathy suspected
Treatment of burning feet:
| Drug | Notes for This Patient |
|---|---|
| Pregabalin | First-line for neuropathic pain; reduce dose for eGFR 38 (use 25-75 mg/day, start very low in elderly); sedation + fall risk - caution |
| Gabapentin | Requires dose reduction at eGFR 38 - use 100 mg OD-TDS; fall risk same |
| Duloxetine | Second-line; avoid if eGFR <30; caution in elderly |
| Amitriptyline | Low dose (10-25 mg) - useful but anticholinergic burden in 85-year-old - use with caution |
| Topical capsaicin / lidocaine | Good option - systemic absorption minimal, no renal concerns |
| Alpha-lipoic acid (600 mg OD) | Mild evidence, safe, often used in CKD diabetic neuropathy |
4. Comorbidity Management
HTN:
- ACE inhibitor or ARB is first-line in diabetic CKD with albuminuria (check UACR)
- If already on RAS blocker, the ADA 2025 guidelines recommend adding finerenone (nonsteroidal MRA) if persistent albuminuria (eGFR >25, normal potassium)
- BP target in 85-year-old: <140/90 mmHg (avoid aggressive lowering - orthostatic hypotension risk)
- Monitor K+ and creatinine carefully
Dyslipidemia:
- Continue/start moderate-intensity statin (atorvastatin 20-40 mg, rosuvastatin 10-20 mg)
- No dose adjustment for CKD 3b with statins
- LDL target: <70 mg/dL (high CV risk)
5. Key Safety Priorities in an 85-Year-Old
- Avoid hypoglycemia above all - it is more dangerous than HbA1c 8% in this age group
- Deprescribe if regimen becomes complex - 2026 frailty-informed deprescribing framework supports simplification
- Fall risk - pregabalin, gabapentin, alpha-blockers for HTN, hypoglycemia all increase fall risk
- Renal monitoring - eGFR at CKD 3b needs monitoring every 3-6 months; adjust drug doses as eGFR changes
- Polypharmacy review - HTN + dyslipidemia + DM in an 85-year-old likely means 8-10 medications; periodic deprescribing review is essential
- Check UACR - determines whether SGLT2i for renoprotection is appropriate and whether RAS blocker is needed
Summary Action Points
- Start Linagliptin 5 mg OD (preferred antidiabetic - safe in CKD, no hypoglycemia)
- HbA1c target 7.5-8% - current 7.8% is acceptable; avoid over-tightening
- Check UACR - guides SGLT2i and RAS blocker decisions
- Investigate burning feet: NCS/EMG, TSH, LFTs, CBC (for high B12 cause)
- Start topical treatment or low-dose pregabalin (renally adjusted) for neuropathic pain
- ACE-I/ARB if UACR >30 mg/g (CKD + HTN + diabetes)
- Finerenone if on max RAS blocker and persistent albuminuria, K+ normal, eGFR >25
- Statin for dyslipidemia (LDL <70 mg/dL target)
- Monitor renal function every 3 months, adjust medications accordingly
This is a shared conversation. Sign in to Orris to start your own chat.